Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
PL02 - Plenary 2: Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)
- 06:30 - 08:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
- Moderators:David Harpole, Tetsuya Mitsudomi
-
+
PL02.03 - Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
06:47 - 06:57 | Presenter: Luis Paz-Ares
- Abstract
Loading...
-
+
MA07 - Liquid Biopsy Applications for Immuno-oncology, Targeted Therapies, and Early Stage NSCLC
- 10:45 - 11:45
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
-
+
MA07.01 - Dynamic Liquid Biopsy During Immunotherapy Anticipates Hyperprogression and Early Death in Advanced Non-Small Cell Lung Cancer
10:45 - 10:50 | Presenter: Laura Bonanno
- Abstract
Loading...
-
+
PL02A - Plenary 2: Presidential Symposium (Rebroadcast) (Japanese, Mandarin, Spanish Translation Available)
- 14:30 - 16:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
- Moderators:David Harpole, Tetsuya Mitsudomi
-
+
PL02A.03 - Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
14:47 - 14:57 | Presenter: Luis Paz-Ares
- Abstract
Loading...
